Phase I Trial of Carboplatin and Etoposide in Combination With Everolimus (RAD001) in Advanced Solid Tumors, With Emphasis on Small Cell Lung Cancer (SCLC).

Trial Profile

Phase I Trial of Carboplatin and Etoposide in Combination With Everolimus (RAD001) in Advanced Solid Tumors, With Emphasis on Small Cell Lung Cancer (SCLC).

Discontinued
Phase of Trial: Phase I

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Everolimus (Primary) ; Carboplatin; Etoposide
  • Indications Small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Feb 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 23 Jul 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 30 Mar 2010 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top